Pfizer (PFE) Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031

Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement ...

Pfizer’s Foes in Bench Trial Over Vyndamax Copies Down to Hikma

Pfizer Inc.'s agreements dropping two generic-drug makers from a patent case over copies of its blockbuster heart drug Vyndamax left Hikma Pharmaceuticals Plc the last remaining defendant for a bench ...

Pfizer says cancer therapy beats standard therapy in late-stage blood cancer study

Pfizer Inc. PFE on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab) ...

Pfizer stock is declining today: What's happening?

Pfizer Inc PFE shares are dipping on Tuesday. The company announced a series of settlement agreements that extend the effective U.S. patent life of Vyndamax, its treatment for transthyretin‑mediated ...
Pharmabiz

Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma

Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma: New York Thursday, April 30, 2 ...
Las Vegas Sun

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...
Pharmabiz

Pfizer reaches settlement agreements with Dexcel Pharma, Hikma Pharma & Cipla for infringement of patents relating to Vyndamax

Pfizer Inc. announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the US District ...

Pfizer’s Deal With Hikma Ends Patent Trial on Vyndamax Copy (1)

Pfizer Inc. agreed to end a dispute with Hikma Pharmaceuticals Plc after one day of trial, resolving the last remaining ...

$4+ Billion OTC Dry Eye Drops Market Analysis Report 2026: Pfizer, Johnson & Johnson Services, and Novartis International Dominate

Key opportunities include capitalizing on rising screen time, increased demand for preservative-free & advanced formulations, ...
The Caledonian-Record

Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

(NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Pfizer (PFE) and Guardant Health (GH)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Phathom Pharmaceuticals , Pfizer and Guardant Health . Claim 55% Off TipRanks. Unlock hedge fund- ...

Pfizer Shareholders Reaffirm Leadership, Governance at 2026 Meeting

Pfizer ( (PFE)) has shared an update. Pfizer shareholders held their Annual Meeting on April 23, 2026, where they re-elected the full slate of board nominees, including Chief Executive Albert Bourla ...